

AMENDMENTS TO THE CLAIMS:

1-74 (Cancelled).

①✓

75 (Currently amended). A method for treating ~~or preventing~~ an ^{Scope?} (autoimmune disorder, ~~proliferative disorder, or infectious disease~~) comprising administering to a mammal an anti-CD91 antibody that binds alpha (2) macroglobulin receptor in an amount effective to treat ~~or prevent~~ the autoimmune disorder, ~~proliferative disorder, or infectious disease~~ in the mammal.

76-96 (Cancelled).

97 (Currently amended). The method of claim 75, wherein the antibody ~~modulates~~ interferes with the interaction of the alpha (2) macroglobulin receptor with a heat shock protein.

98 (Cancelled).

99 (Previously amended). The method of claim 97, wherein the heat shock protein is gp96.

100 (Previously amended). The method of claim 97, wherein the heat shock protein is Hsp70.

101 (Previously amended). The method of claim 97, wherein the heat shock protein is Hsp90.

102 & 103 CANCELLED

104 - 110 (Cancelled).

111 (Currently amended). The method of claim ~~110~~ 75, wherein the anti-CD91 antibody ~~modulates~~ interferes with the interaction of alpha (2) macroglobulin receptor with an alpha (2) macroglobulin receptor-ligand.

112 (Currently amended). The method of claim ~~110 or~~ 111, wherein the autoimmune disorder is selected from the group consisting of: insulin dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, pernicious anemia, autoimmune thyroiditis, idiopathic Addison's disease, vitiligo, gluten-sensitive enteropathy, Graves' disease, myasthenia gravis, autoimmune neutropenia, idiopathic thrombocytopenia purpura, rheumatoid arthritis, cirrhosis, pemphigus vulgaris, autoimmune infertility, Goodpasture's disease, bullous pemphigoid, discoid lupus, ulcerative colitis, and dense deposit disease.

113 -

113 - 121 (Cancelled).

122 (Currently amended). The method of claim 75, 97, ~~104, 105, 107, 108, 110 or~~ 99-101, 111, or 112 wherein the anti-CD91 antibody is an antagonist of the alpha (2) macroglobulin receptor.

C - 122 - 128 CANCELLED

129 (Currently amended). The method of any one of claims 75, 97, ~~104, 105, 107, 108, 110 or~~ 99-101, 111, or 112 wherein the mammal is a human.

130-131 (Cancelled).

132 (Currently amended). The method of any one of claims 75, 97, ~~104, 105, 107, 108, 110~~ 99-101, or 111, or 112, wherein the antibody is purified.

133 (New). A method for inhibiting re-presentation of an antigenic peptide, comprising administering to a mammal an anti-CD91 antibody that binds alpha (2) macroglobulin receptor in an amount effective to inhibit re-presentation of an antigenic peptide.

134 (New). The method of claim 133, wherein the antibody interferes with the interaction of the alpha (2) macroglobulin receptor with a heat shock protein.

135 (New). The method of claim 134, wherein the heat shock protein is gp96.

136 (New). The method of claim 134, wherein the heat shock protein is Hsp70.

137 (New). The method of claim 134, wherein the heat shock protein is Hsp90.

138 (New). The method of claim 133, wherein the anti-CD91 antibody interferes with the interaction of alpha (2) macroglobulin receptor with alpha (2) macroglobulin receptor.

139 (New). The method of claim 133, wherein inhibiting re-presentation of the antigenic peptide prevents an autoimmune disorder.

140 (New). The method of claim 139, wherein the autoimmune disorder is selected from the group consisting of: insulin dependent diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, polymyositis, chronic active hepatitis, mixed connective tissue disease, primary biliary cirrhosis, pernicious anemia, autoimmune thyroiditis, idiopathic Addison's disease, vitiligo, gluten-sensitive enteropathy, Graves' disease, myasthenia gravis, autoimmune neutropenia, idiopathic thrombocytopenia purpura, rheumatoid arthritis, cirrhosis, pemphigus vulgaris, autoimmune infertility,

Goodpasture's disease, bullous pemphigoid, discoid lupus, ulcerative colitis, and dense deposit disease.

141 (New). The method of claim 133, 134, or 138, wherein the anti-CD91 antibody is an antagonist of the alpha (2) macroglobulin receptor.

142 (New). The method of any one of claims 133, 134, 138 or 139, wherein the mammal is a human.

143 (New). The method of any one of claims 133, 134, 138 or 139, wherein the antibody is purified.

144 (New). The method of any one of claims 75, 97, 99-101, 111, 112, 133, 134, 138 or 139, wherein the antibody is monoclonal or polyclonal.

145 (New). The method of any one of claims 75, 97, 99-101, 111, 112, 133, 134, 138 or 139, wherein the antibody is humanized or chimeric.

146 (New). The method of any one of claims 75, 97, 99-101, 111, 112, 133, 134, 138 or 139, wherein the antibody is a single chain antibody or Fab fragment.

147 (New). The method of any one of claims 75, 97, 99-101, 111, 112, 133, 134, 138 or 139, wherein the antibody is an epitope-binding fragment of an antibody.